Lincoln News Today | 2 Min News | The Daily News Now!
A breakthrough in pancreatic cancer treatment is here: daraxonrasib, an experimental pill targeting the KRAS gene mutation found in 90% of cases, has doubled survival time in stage four patients—from 6.5 to 13 months—offering hope where few options remain. Available now via expanded access, it’s a daily oral treatment, not an infusion, and while side effects like facial rash exist, they’re manageable. The drug’s potential extends beyond pancreatic cancer, with implications for lung and colorectal cancers too. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/2d64f726fc456b04
300 episodes
Comments
0Be the first to comment
Sign up now and become a member of the Lincoln News Today | 2 Min News | The Daily News Now! community!